Behcet's Syndrome
Behcet's syndrome is an uncommon, chronic, multisystemic, inflammatory disorder with varied features. Behcet's disease typically affects arteries and veins of any size in all locations. There is unique expertise and an overarching approach needed to address the challenges in rare cardiovascular disease drug discovery. Focused on the progress of the therapy of diseases such as Behcet's disease, Protheragen provides comprehensive drug discovery and development services.
Introduction to Behcet's Syndrome
Behcet's syndrome is a chronic multisystemic inflammatory disease, belonging to the variable vasculitis group, and is characterized by oral ulcers, genital ulcers, and uveitis. Additionally, it may affect other organ systems including musculoskeletal, gastrointestinal, cardiovascular, and neurologic. Cardiovascular manifestations of Behcet's disease are significantly associated with its morbidity and mortality. The worldwide prevalence of Behcet's syndrome is 10.3 / 100000 with high geographic variability.
Fig.1 Characteristic involved arteries in Behcet's disease. (Kim J., 2024)Pathogenesis of Behcet's Syndrome
Multiple genetic and environmental factors come into play in the initiation and exacerbation of the disease.HLA-B51 and MHC class I allele are linked with Behcet's disease. Genome-wide association studies have also identified interleukin (IL)-10, IL-23R-IL-12RB2, IL-1A-IL-1B, CCR1, and ERAP1 as Behcet's disease susceptibility genes. Immunological etiology is also linked to the pathogenesis of tissue destruction. Hyperactivation of neutrophils, natural killer (NK) cells, Th 1 and Th 17 cells are often quoted as the major immunologic abnormality.
Fig.2 Cardiovascular lesions of Behcet's disease. (Kim J., 2024)Therapeutics Development for Behcet's Syndrome
| Drug Name | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| HSK44459 | One small molecule drug that regulates immune responses and inhibits inflammation by working on a particular molecular pathway. | PDE4B | NCT06902428 | Phase II |
| Rivaroxaban | Inhibiting factor Xa to decrease the risk of vaso-thrombosis associated with vascular inflammation present in the disease. | Factor Xa | NCT06925698 | Phase III |
| RAY121 | Suppresses the classical complement pathway to inhibit potential inflammation and autoimmune response in Behcet's disease. | / | NCT06723106 | Phase I |
| Azathioprine | The immune system is suppressed by inhibiting purine synthesis, thus reducing lymphocyte proliferation and the inflammatory response. | DNA | / | Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
By combining diagnostics, therapeutics, and disease model development, we are shortening the time from discovery to preclinical validation. Based on rich experience in the investigation of pharmacokinetics and drug safety assessments, we offer a full range of preclinical services. With state-of-the-art technologies and comprehensive methods, our staff works hard to verify each and every therapeutic in all of our services. This integrated method accelerates development and increases the probability of a successful experiment.
Therapeutic Development Services
Animal Model Development for Behcet's Syndrome
Models of Behcet's syndrome in animals are essential to shed light on the complicated immunopathogenesis as well as for testing new therapy. Our company is committed to overcoming these challenges with customized Behcet's syndrome animal models utilizing gene editing and induced strategies to resemble phenotypes and immune pathways.
Through the introduction or modification of certain genes associated with the disease, technology makes the animal model with Behcet's syndrome.
Optional models:
- HLA-B*51 transgenic mouse model
- Other models
Experimental Behcet's syndrome is the result of the induction of animals by exposing them to specific stimuli or antigens that induce Behcet's syndrome.
Optional models:
- Herpes simplex virus type 1-induced model
- α-tropomyosin-induced model
- HSP-60 peptide-induced model
- S antigen-induced model
- Other models
Choosing us as a research partner will provide you with specialist resources and bespoke assistance. Protheragen's efforts are dedicated to facilitating high-quality research in rare cardiovascular diseases and to providing customized solutions to meet your specific requirements. Advance your drug discovery programs, get in touch today to discover how we can help with your innovative drugs.
References
- Kim, Jinhyun. "Cardiovascular Manifestations in Behcet's Disease." Yonsei medical journal 65.9 (2024): 493-500.
- Emmi, Giacomo et al. "Behcet's syndrome." Lancet (London, England) 403.10431 (2024): 1093-1108.
For research use only, not for clinical use.